Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.
about
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia'Acute myeloid leukemia: a comprehensive review and 2016 update'Measurable residual disease testing in acute myeloid leukaemia.Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationHematopoietic stem-cell transplantation for advanced systemic mastocytosis.Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.Sequencing small genomic targets with high efficiency and extreme accuracy.A multigene array for measurable residual disease detection in AML patients undergoing SCTAllogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.Relapse assessment following allogeneic SCT in patients with MDS and AML.Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML.Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
P2860
Q26771438-58E06C45-6171-4D4C-8973-9859B937E433Q28072539-5449C0DD-0C85-4B30-8923-64A86EB892BAQ30234914-75BA354D-851E-484C-9055-124D4E21AFF7Q30408294-700C8D60-7113-4BF9-9B96-C29B302566A5Q34627218-20F85B3C-9B91-4DAD-9EBD-C7CFFE9F1DC6Q34664111-F69BC0BC-5150-403F-9295-AA9EAF0AE1C5Q34979564-367D041A-C043-48B0-A11B-073014216F0CQ35554760-4DB23AD9-789A-4EC5-B25A-9A633C9B939BQ35582360-549C5C58-D075-4BC5-A77D-A9F9E74AABA3Q36914475-936585E8-AF66-42AA-961A-8D765D35BAFAQ37072126-2C2B679D-7FB6-4007-92B1-EB7CD5A41E3BQ37141503-639A50F7-2E4A-4655-8A96-24D1BC333A89Q37151698-222296DA-5CD0-41B3-BA99-388C85DD4114Q38199623-68EB6168-DA03-4AC9-8B42-57EC35815E05Q38452047-AD052C41-F83B-4AAE-AF7A-434A9B763E2BQ38568355-CABD94F5-BB70-416D-8150-DA7210ED822DQ38672646-4655B2E6-6F7D-44E2-A154-A779162C6A94Q38863489-251260AF-9410-4E5E-8FA8-549C4697807FQ38886247-B40C26EF-8138-4302-A61E-9DB9A2DEA7E4Q39132424-0D92F491-C7AB-45FA-9632-4609D8276AD9Q39285841-91110F52-DE73-489E-8095-62EFD497AED6Q40064058-854B9E90-DD39-45BF-A663-43EBBC107E61Q42974471-F65A552E-BB8A-41A9-93F7-E851C65A5813Q45423288-D26D43E8-4CFE-4FF8-AAA4-FAC92E8A3663Q47706549-B8B476D3-2437-4379-8401-A72FCD3951EBQ47804815-FDE1BA1A-BB61-4E0F-A34B-A6FEAB4411E7Q53094956-582C15DA-F110-4F4F-B672-D03627684350Q58724470-8B055B10-D2C1-45EF-A4FC-847009A052AC
P2860
Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Prognostic and therapeutic imp ...... splantation in acute leukemia.
@en
type
label
Prognostic and therapeutic imp ...... splantation in acute leukemia.
@en
prefLabel
Prognostic and therapeutic imp ...... splantation in acute leukemia.
@en
P2860
P356
P1476
Prognostic and therapeutic imp ...... splantation in acute leukemia.
@en
P2093
R B Walter
S A Buckley
P2860
P2888
P304
P356
10.1038/BMT.2012.139
P407
P577
2012-07-23T00:00:00Z
P5875
P6179
1032048134